Education
About Us
Working with TipRanks
Follow Us
Hikma Pharmaceuticals (GB:HIK)
:HIK
HIK Stock Chart & Stats
Day’s Range― - ―
52-Week Range1,750.00p - 2,360.00p
Previous CloseN/A
Volume7.28K
Average Volume (3M)608.81K
Market Cap
£4.36B
Enterprise Value5.05B
Total Cash (Recent Filing)$205.00M
Total Debt (Recent Filing)$1.19B
Price to Earnings (P/E)15.5
Beta0.77
Next Earnings
Aug 07, 2025EPS EstimateN/A
Last Dividend Ex-Date
Mar 20, 2025Dividend Yield3.16%
Share Statistics
EPS (TTM)1.27
Shares Outstanding221,886,460
10 Day Avg. Volume536,972
30 Day Avg. Volume608,811
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)N/A
Price to Sales (P/S)1.92
Price to Cash Flow (P/CF)14.70
P/FCF Ratio20.20
Enterprise Value/Market Cap1.16
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit3.59
Enterprise Value/Ebitda3.21
Forecast
1Y Price Target
2,427.00pPrice Target Upside23.64% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
---
Hikma Pharmaceuticals News
PremiumCompany Announcements
Hikma Pharmaceuticals Releases 2024 Annual Report and AGM Notice
PremiumCompany Announcements
Hikma Pharmaceuticals Announces Vesting of Executive Share Awards
PremiumCompany Announcements
Hikma Pharmaceuticals to Announce 2024 Financial Results
PremiumCompany Announcements
Hikma Pharmaceuticals Discloses PDMR Share Disposal---
Bulls Say, Bears Say
Bulls Say
Contract WinsThe Generics business secured a significant new long-term CDMO contract, enhancing manufacturing facility utilization and supporting future growth.
Financial PerformanceHikma delivered a strong performance with a 6% beat to core EBIT compared to initial 2024 guidance, showcasing its ability to navigate challenges effectively.
Growth ProspectsSales increased 8% to $769m, driven by a strategic shift in portfolio mix towards oncology and chronic illness medications, indicating robust growth potential.
Bears Say
Earnings GuidanceThe FY25 guidance suggests 'mid-30s' core EBIT, which could imply a wider outcome range than the typically more specific guidance provided in the past.
Financial ForecastThere is a 2% reduction in FY25 core EBIT forecast and a 5% reduction in adjusted EPS, reflecting the impact of higher interest charges.
---
Options Prices
Currently, No data available
---
Ownership Overview
7.71% Insiders
5.11%
Mutual Funds
― Other Institutional Investors
78.22% Public Companies and
Individual Investors
HIK FAQ
What was Hikma Pharmaceuticals’s price range in the past 12 months?
Hikma Pharmaceuticals lowest share price was 1750.00p and its highest was 2360.00p in the past 12 months.
What is Hikma Pharmaceuticals’s market cap?
Hikma Pharmaceuticals’s market cap is £4.36B.
When is Hikma Pharmaceuticals’s upcoming earnings report date?
Hikma Pharmaceuticals’s upcoming earnings report date is Aug 07, 2025 which is in 128 days.
How were Hikma Pharmaceuticals’s earnings last quarter?
Hikma Pharmaceuticals released its earnings results on Feb 26, 2025. The company reported 0.467p earnings per share for the quarter, beating the consensus estimate of N/A by 0.467p.
Is Hikma Pharmaceuticals overvalued?
According to Wall Street analysts Hikma Pharmaceuticals’s price is currently Undervalued.
Does Hikma Pharmaceuticals pay dividends?
Hikma Pharmaceuticals pays a Annually dividend of 37.805p which represents an annual dividend yield of 3.16%. See more information on Hikma Pharmaceuticals dividends here
What is Hikma Pharmaceuticals’s EPS estimate?
Hikma Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Hikma Pharmaceuticals have?
Hikma Pharmaceuticals has 221,886,460 shares outstanding.
What happened to Hikma Pharmaceuticals’s price movement after its last earnings report?
Hikma Pharmaceuticals reported an EPS of 0.467p in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -6.185%.
Which hedge fund is a major shareholder of Hikma Pharmaceuticals?
Currently, no hedge funds are holding shares in GB:HIK
---
Hikma Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
2,427.00p (23.64% Upside)
2,427.00p (23.64% Upside)
Blogger Sentiment
Bullish
GB:HIK Sentiment 70%
Sector Average 69%
Sector Average 69%
Insider Transactions
Sold Shares
Worth £90.6K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
5.42%
12-Months-Change
Fundamentals
Return on Equity
15.79%
Trailing 12-Months
Asset Growth
11.64%
Trailing 12-Months
Company Description
Hikma Pharmaceuticals
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.
---
HIK Stock 12 Month Forecast
Average Price Target
2,427.00p
▲(23.64% Upside)
Technical Analysis
Best Analysts Covering HIK
1 Year
1 Year Success Rate
11/15 ratings generated profit
1 Year Average Return
+7.13%
assigned a buy rating 8 months ago
Copying Peter Verdult's trades and holding each position for 1 Year would result in 73.33% of your transactions generating a profit, with an average return of +7.13% per trade.
---